Sanjivani Paranteral [SANJIVIN] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Sanjivani Paranteral
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sanjivani Paranteral wins in 6 metrics, Sun Pharmaceutical wins in 13 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sanjivani Paranteral | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.50 | 37.73 | Sanjivani Paranteral |
| Price-to-Book Ratio | 7.12 | 5.42 | Sun Pharmaceutical |
| Debt-to-Equity Ratio | 20.42 | 3.26 | Sun Pharmaceutical |
| PEG Ratio | -50.71 | -1.94 | Sanjivani Paranteral |
| EV/EBITDA | 26.30 | 23.98 | Sun Pharmaceutical |
| Profit Margin (TTM) | 11.34% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | 13.88% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 13.88% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 20.31% | 15.08% | Sanjivani Paranteral |
| Return on Assets (TTM) | 10.35% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $-179.46M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | N/A | 1.26% | N/A |
| 1-Year Return | -25.39% | -13.00% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 3.91 | 7.28 | Sanjivani Paranteral |
| Enterprise Value | $2.78B | $3,678.87B | Sun Pharmaceutical |
| EV/Revenue Ratio | 3.88 | 6.84 | Sanjivani Paranteral |
| Gross Profit Margin (TTM) | 37.88% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $61 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $6.60 | $43.23 | Sun Pharmaceutical |
| Beta (Stock Volatility) | -0.88 | 0.28 | Sanjivani Paranteral |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Sanjivani Paranteral vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sanjivani Paranteral | 0.27% | -2.46% | -9.50% | 2.13% | -3.83% | -41.73% |
| Sun Pharmaceutical | -0.10% | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sanjivani Paranteral | -25.39% | 348.49% | 2,289.37% | 574.09% | 240.66% | 275.44% |
| Sun Pharmaceutical | -13.00% | 69.49% | 239.84% | 85.82% | 711.29% | 2,598.03% |
News Based Sentiment: Sanjivani Paranteral vs Sun Pharmaceutical
Sanjivani Paranteral
News based Sentiment: POSITIVE
October was a positive month for Sanjivani Paranteral, marked by stock price increases and a notable increase in promoter holding. While shifts in other investor groups require monitoring, the overall trend suggests growing confidence in the company's prospects.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a month of significant contrasts for Sun Pharma. While the company demonstrated revenue growth and made strategic acquisitions, the imposition of a 100% US tariff on Indian pharmaceuticals presents a major headwind. This combination of positive and negative developments creates a mixed investment outlook.
Performance & Financial Health Analysis: Sanjivani Paranteral vs Sun Pharmaceutical
| Metric | SANJIVIN | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.83B | ₹4.01T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,866 | 3,168,435 |
| 90 Day Avg. Volume | 10,141 | 2,778,768 |
| Last Close | ₹223.05 | ₹1,653.10 |
| 52 Week Range | ₹203.10 - ₹396.95 | ₹1,548.00 - ₹1,947.00 |
| % from 52W High | -43.81% | -15.10% |
| All-Time High | ₹396.95 (Dec 30, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -43.81% | -15.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.10% |
| Quarterly Earnings Growth | 0.01% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.19% |
| Operating Margin (TTM) | 0.14% | 0.24% |
| Return on Equity (TTM) | 0.20% | 0.15% |
| Debt to Equity (MRQ) | 20.42 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹31.98 | ₹300.99 |
| Cash per Share (MRQ) | ₹2.04 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹35.94M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹80.97M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.26% |
| Last 12-Month Dividend | N/A | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Sanjivani Paranteral vs Sun Pharmaceutical
| Metric | SANJIVIN | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.50 | 37.73 |
| Forward P/E | N/A | 49.91 |
| PEG Ratio | -50.71 | -1.94 |
| Price to Sales (TTM) | 3.91 | 7.28 |
| Price to Book (MRQ) | 7.12 | 5.42 |
| Market Capitalization | ||
| Market Capitalization | ₹2.83B | ₹4.01T |
| Enterprise Value | ₹2.78B | ₹3.68T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.88 | 6.84 |
| Enterprise to EBITDA | 26.30 | 23.98 |
| Risk & Other Metrics | ||
| Beta | -0.88 | 0.28 |
| Book Value per Share (MRQ) | ₹31.98 | ₹300.99 |
Financial Statements Comparison: Sanjivani Paranteral vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANJIVIN | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹178.92M | ₹137.86B |
| Cost of Goods Sold | ₹111.14M | ₹28.15B |
| Gross Profit | ₹67.78M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹24.84M | ₹33.72B |
| EBITDA | ₹26.83M | ₹47.66B |
| Pre-Tax Income | ₹23.01M | ₹31.73B |
| Income Tax | ₹5.70M | ₹8.70B |
| Net Income (Profit) | ₹17.31M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANJIVIN | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹14.85M | ₹102.69B |
| Total Current Assets | ₹341.79M | ₹526.24B |
| Total Current Liabilities | ₹317.92M | ₹181.94B |
| Long-Term Debt | ₹52.89M | ₹3.58B |
| Total Shareholders Equity | ₹398.71M | ₹724.86B |
| Retained Earnings | ₹-427.89M | ₹578.62B |
| Property, Plant & Equipment | ₹386,420 | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANJIVIN | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANJIVIN | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 3,866 | 3,168,435 |
| Average Daily Volume (90 Day) | 10,141 | 2,778,768 |
| Shares Outstanding | 11.88M | 2.40B |
| Float Shares | 5.83M | 1.06B |
| % Held by Insiders | 0.58% | 0.56% |
| % Held by Institutions | 0.01% | 0.25% |
Dividend Analysis & Yield Comparison: Sanjivani Paranteral vs Sun Pharmaceutical
| Metric | SANJIVIN | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹21.00 |
| Last 12-Month Dividend Yield | N/A | 1.26% |
| 3-Year Avg Annual Dividend | N/A | ₹14.67 |
| 3-Year Avg Dividend Yield | N/A | 0.46% |
| 3-Year Total Dividends | N/A | ₹44.00 |
| Ex-Dividend Date | N/A | Jul 07, 2025 |